Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol
Status:
RECRUITING
Trial end date:
2030-06-30
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for Alzheimer's disease, mild cognitive impairment, other forms of dementia detection and monitoring. The main question it aims to answer is:
Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called 18F-Florbetapir or 18F-Flutemetamol and be imaged on a new type of high-sensitivity PET scanner for up to 3 hours
Phase:
PHASE2
Details
Lead Sponsor:
Akiva Mintz
Treatments:
Blood Specimen Collection florbetapir flutemetamol Magnetic Resonance Spectroscopy